Use of blocking agents of bone morphogenic protein (BMP) signalling for the treatment of neuroinflammatory and neurodegenerative diseases
The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the pharmaceutical compositions of the invention.
1. A method for treatment of a subject suffering from multiple sclerosis, comprising administering to said subject a therapeutically effective amount of an anti-Bone Morphogenic Protein (BMP) antibody or a functional fragment thereof and a pharmaceutically acceptable carrier, wherein said antibody is an antibody directed against BMP-2 and BMP-4.
2. A method according to claim 1 , wherein said anti-BMP antibody is a monoclonal antibody.
3. A method according to claim 2 , wherein said monoclonal antibody is a chimeric, humanized, or human antibody.
4. A method according to claim 1 , further comprising administering to said subject at least one additional therapeutic agent.